ACADIA Pharmaceuticals Inc. (ACAD): one to watch?

Speculative buy — the crash is about a failed future Alzheimer's drug bet, not the profitable core business, but pipeline disappointment risk remains real.

👀 WATCH Fundamentals67/100

Fell 20% in 10 trading day(s) — now $22.18

Why ACAD dropped

ACAD fell because its Phase 2 RADIANT trial for remlifanserin (a future Alzheimer's psychosis drug, not yet generating any revenue) narrowly missed its main statistical goal, even though it still showed benefit on a secondary measure and is moving into Phase 3.

Fwd P/E 24.9Op margin 12.3%Rev growth 16.4%Debt/equity 5.7%Analyst upside 50.2%

How this scored 67/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 33.4%

✅ Generates cash Free cash flow $69M

✅ Not drowning in debt Debt/equity 5.7% (limit 200%)

✅ Can pay its bills Current ratio 3.4 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 20/25

Operating margin 12.3% 4/9

Net profit margin 33.4% 8/8

Return on equity 35.7% 8/8

Growth Is it getting bigger, or dying? 11/25

Revenue growth 16.4% 6/9

Earnings growth 13.3% 5/8

Expected profit change -60.1% 0/8

Value Is it cheap right now? 11/25

Forward P/E 24.9 5/10

PEG ratio 50.9 0/8

Analyst target upside 50.2% 6/7

Balance sheet Will it survive? 25/25

Debt / equity 5.7% 10/10

Current ratio 3.4 8/8

Free cash flow $69M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for ACAD — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-09-25. Research only — not financial advice.